A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed Stage III B or Stage IV squamous non-small cell lung cancer (NSCLC) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * No prior chemotherapy for squamous NSCLC * Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR status is unknown * Radiographic evidence of disease Exclusion Criteria: * Prior systemic treatment for Stage IIIB or IV squamous NSCLC * NSCLC with histology classified as adenocarcinoma, large cell, mixed adenosquamous, or NSCLC not otherwise specified (NOS) * Prior exposure to experimental treatment targeting either the HGF or Met pathway * Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator * Uncontrolled brain metastases and treatment by neurosurgical resection or brain biopsy within 4 weeks prior to Day 1 of Cycle 1 * History of another malignancy in the previous 3 years except for prior history of in situ cancer or basal or squamous cell skin cancer * Pregnant or lactating women * Uncontrolled diabetes * Impaired bone marrow, liver or renal function as defined by protocol * Significant history of cardiovascular disease * Positive for HIV infection